Abstract:Liver tissues were obtained from 20 liver cancer patients from Thailand, an area where the incidence of this tumour is high and where exposure to aflatoxin occurs. The expression of hepatic cytochrome P450s (P450) and glutathione S-transferase (GST) was examined and this expression was compared to the in vitro metabolism of aflatoxin B1 (AFB1). There was a > 10-fold inter-individual variation in expression of the various P450s including CYP3A4 (57-fold), CYP2B6 (56-fold) and CYP2A6 (120-fold). Microsomal metabolism of AFB1 to AFB1 8,9-epoxide (as measured by AFB1 tris-diol formation) and aflatoxin Q1 (AFQ1), the major metabolite produced, was significantly correlated with CYP3A3/4 expression (P < 0.001) and, to a lesser extent, with CYP2B6 expression (P < 0.01). There was a significantly reduced expression of major P450 proteins in microsomes from liver tumours compared to microsomes from the paired normal liver when analysed by Western immunoblot analysis. The production of AFQ1 and AFB1 tris-diol was almost uniformly reduced in tumours, but interestingly, the production of AFP1 was significantly increased. The immunoreactive expression of the major human classes of cytosolic GSTs (alpha, mu and pi) was also analyzed in normal and tumorous liver tissue. The expression of GSTA (alpha) and GSTM (mu) class proteins was markedly decreased and GSTP (pi) increased in the majority of tumour cytosols compared to normal liver. The cytosolic GST activity (1-chloro-2,4-dinitrobenzene conjugation) was significantly lower in liver tumours compared to normal liver (193 +/- 149 versus 875 +/- 299 nmol/min/mg, P < 0.0001), as was glutathione peroxidase (GPx) activity (cumene hydroperoxide) (26 +/- 23 versus 70 +/- 26 nmol/min/mg respectively, P < 0.005). Ten out of 14 individuals (71%) were homozygous null when genotyped for GSTM1. There was no detectable conjugation of AFB1 8,9-epoxide to glutathione by cytosol either from tumorous or normal liver. Thus, capacity of human cytosols to conjugate reactive AFB1 metabolites to GSH resembled AFB1-sensitive species such as rat, trout and duck rather than resistant species such as mouse and hamster. These data indicate a strong capacity of multiple forms of human hepatic P450s to metabolize AFB1 to both the reactive intermediate AFB1 8,9-epoxide and the detoxification product AFQ1. These results suggest that in view of the lack of significant GST-mediated protection against AFB1 in human liver, variations in expression of hepatic P450, due either to genetic polymorphisms or to modulation by environmental factors, may be important determinants in the risk of liver cancer development in AFB1-exposed populations.

Integrated data from intravital imaging and HPLC–MS/MS analysis reveal large interspecies differences in AFB1 metabolism in mice and rats

Comparative metabolism of aflatoxin B1 in mouse, rat and human primary hepatocytes using HPLC–MS/MS

Systems Responses of Rats to Aflatoxin B1 Exposure Revealed with Metabonomic Changes in Multiple Biological Matrices

Establishment of an Isotope Dilution Lc-Ms/Ms Method Revealing Kinetics and Distribution of Co-Occurring Mycotoxins in Rats

Metabolism of aflatoxins: key enzymes and interindividual as well as interspecies differences

Comparative activities of glutathione-S-transferase and dialdehyde reductase toward aflatoxin B1 in livers of experimental and farm animals.

Integration of Transcriptomic and Metabolomic Data to Compare the Hepatotoxicity of Neonatal and Adult Mice Exposed to Aristolochic Acid I

AFB1-induced Mice Liver Injury Involves Mitochondrial Dysfunction Mediated by Mitochondrial Biogenesis Inhibition

Oxidative DNA Damage and Multi-Organ Pathologies in Male Mice Subchronically Treated with Aflatoxin B1.

In vitro metabolism of aflatoxin B1 by normal and tumorous liver tissue from Thailand

Integrated analysis of transcriptomics and metabonomics profiles in aflatoxin B1-induced hepatotoxicity in rat

Aflatoxin B1Induced Compositional Changes in Gut Microbial Communities of Male F344 Rats

HPLC–MS/MS method for the simultaneous determination of aflatoxins in blood: toxicokinetics of aflatoxin B 1 and aflatoxin M 1 in rats

Effects of saturated and unsaturated dietary fat on aflatoxin B1 metabolism

Arsenic Relative Bioavailability in Contaminated Soils: Comparison of Animal Models, Dosing Schemes, and Biological End Points

Elucidation of the species differences of epyrifenacil-induced hepatotoxicity between mice and humans by mass spectrometry imaging analysis in chimeric mice with humanized liver

Differential Mutagenicity Of Aflatoxin B-1 In The Liver Of Neonatal And Adult Mice

Hepatotoxic Effects of Mycotoxin Combinations in Mice

Elevation of 8-hydroxydeoxyguanosine in DNA from isolated mouse lung cells following in vivo treatment with aflatoxin B(1)

Strain Differences in Arsenic-Induced Oxidative Lesion Via Arsenic Biomethylation Between C57bl/6j and 129x1/svj Mice

Comparative toxicoproteogenomics of mouse and rat liver identifies TCDD-resistance genes